(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of 287.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.23%.
Longeveron's revenue in 2026 is $1,199,000.On average, 5 Wall Street analysts forecast LGVN's revenue for 2026 to be $20,782,362, with the lowest LGVN revenue forecast at $11,401,199, and the highest LGVN revenue forecast at $26,874,256. On average, 4 Wall Street analysts forecast LGVN's revenue for 2027 to be $266,834,603, with the lowest LGVN revenue forecast at $22,802,399, and the highest LGVN revenue forecast at $524,943,798.
In 2028, LGVN is forecast to generate $956,467,564 in revenue, with the lowest revenue forecast at $34,203,598 and the highest revenue forecast at $1,932,526,576.